COMMUNIQUÉS West-GlobeNewswire
-
Cuprina Holdings (Cayman) Limited Announces Closing of Public Offering
18/09/2026 -
Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D® Study Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure
17/09/2026 -
BioTech Social Announces Advisory Board to Advance Financial Innovation for Life Science Companies
18/09/2026 -
Roche announces grand opening of its Innovation Center Boston to drive advancements in Cardiovascular, Renal and Metabolic diseases
17/09/2026 -
FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A
17/09/2026 -
AVAVA Announces $45 Million Financing Led by Catalio Capital Management to Accelerate Next Phase of Growth
17/09/2026 -
Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)
17/09/2026 -
MAPS Attends Historic FDA Hearing on Psychedelics
17/09/2026 -
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17/09/2026 -
Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program
17/09/2026 -
argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
17/09/2026 -
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17/09/2026 -
Vireo Growth Inc. Announces Issuance of Shares in Connection with Altmore Settlement
17/09/2026 -
Beta Bionics Announces Closing of $172.5 Million Public Offering of Common Stock
17/09/2026 -
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
17/09/2026 -
Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN
17/09/2026 -
NOMAD POWER SOLUTIONS FILES EXPANDED BUSINESS AND FINANCIAL DISCLOSURE FOLLOWING COMPLETION OF MERGER
17/09/2026 -
Onco360® Has Been Selected as a National Pharmacy Partner for ETCAMAH™ (camizestrant)
17/09/2026 -
Universal Door Meditation Center establishes Thai Pho Mon Awakened Center
17/09/2026
Pages